Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) : Application of Society Guidelines to Clinical Practice
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease affecting 30% of the global population. In this article, we summarize current expert guidelines, review clinical practice implications, and provide insight into the utility of non-invasive tests (NITs).
RECENT FINDINGS: The burden of MASLD is growing with the obesity epidemic, yet disease awareness and diagnosis is low. Patients can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which can advance to liver fibrosis, cirrhosis, hepatic decompensation, and liver cancer. NITs help identify high-risk patients who may benefit from specialty referral and MASH-directed therapy. Global societies offer various recommendations for the screening and diagnosis of MASLD utilizing evidence-based, widely accessible methods such as serum indices, NITs, and liver biopsy. Several targeted steatotic liver disease (SLD) screening tools and novel therapies are under development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current gastroenterology reports - 25(2023), 10 vom: 28. Okt., Seite 213-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilagan-Ying, Ysabel C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 22.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11894-023-00883-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362646775 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362646775 | ||
| 003 | DE-627 | ||
| 005 | 20231226091653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11894-023-00883-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362646775 | ||
| 035 | |a (NLM)37768417 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilagan-Ying, Ysabel C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) |b Application of Society Guidelines to Clinical Practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease affecting 30% of the global population. In this article, we summarize current expert guidelines, review clinical practice implications, and provide insight into the utility of non-invasive tests (NITs) | ||
| 520 | |a RECENT FINDINGS: The burden of MASLD is growing with the obesity epidemic, yet disease awareness and diagnosis is low. Patients can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which can advance to liver fibrosis, cirrhosis, hepatic decompensation, and liver cancer. NITs help identify high-risk patients who may benefit from specialty referral and MASH-directed therapy. Global societies offer various recommendations for the screening and diagnosis of MASLD utilizing evidence-based, widely accessible methods such as serum indices, NITs, and liver biopsy. Several targeted steatotic liver disease (SLD) screening tools and novel therapies are under development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fibrosis-4 score | |
| 650 | 4 | |a Metabolic dysfunction-associated steatotic liver disease | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a NAFLD fibrosis score | |
| 650 | 4 | |a Non-invasive testing | |
| 650 | 4 | |a Nonalcoholic fatty liver disease | |
| 650 | 4 | |a Nonalcoholic steatohepatitis | |
| 650 | 4 | |a Obesity | |
| 700 | 1 | |a Banini, Bubu A |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Joseph K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current gastroenterology reports |d 1999 |g 25(2023), 10 vom: 28. Okt., Seite 213-224 |w (DE-627)NLM108793311 |x 1534-312X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:28 |g month:10 |g pages:213-224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11894-023-00883-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 28 |c 10 |h 213-224 | ||